Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients

Loading...
Loading...

Sanofi SA SNY presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors.

  • Data were shared at the American Society of Hematology (ASH) Annual Meeting. 
  • Fitusiran, an RNAi drug designed to silence the gene that overproduces a protein responsible for clotting suppression.
  • Fitusiran cut patients’ annualized bleeding rate (ARB) rate by 89% over control, demonstrating prophylactic for bleeding episodes as a once-monthly injection. 
  • In this Phase 3 study, dubbed ATLAS-A/B, 50.6% of patients treated with fitusiran had zero treated bleeds during the study compared with just 5% of patients in the on-demand arm.
  • Sanofi revealed safety data from ATLAS-A/B with 19% of patients in the fitusiran arm reporting abnormally high levels of ALT and AST proteins. Meanwhile, there were no reported cases of thrombosis.
  • Sanofi reported updated results from ATLAS-INH showing 24.4% of patients in the study had abnormally high levels of ALT/AST, and two patients presented suspected or confirmed thrombosis. 
  • Price Action: SNY shares are down 1.05% at $48.26 during the market session on the last check Tuesday.
  • Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Posted In: BiotechNewsHealth CareGeneralASH21BriefsHemophiliaHemophilia Ahemophilia BPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...